Abstract
Abstract Background: Transarterial Chemoembolization (TACE) is recommended as a treatment for unresectable Hepatocellular Carcinoma (HCC) in patients with normal compensated liver. The efficacy of TACE in cirrhotic patients with compromised liver function is unknown. Aim of Study: To evaluate the outcome following Tran-sarterial Chemoembolization (TACE) in patients with unap-plicable locoregional therapy in Hepatocellular Carcinoma (HCC). Patients and Methods: This Prospective Cohort study conducted on 50 patients with HCC at Tropical Medicine and Gastroenterology Department Qena University Hospital. Results: 56% of patients reached complete response within one month of treatment in mean duration of follow-up of 58.28 months, 66% of patients had recurrence 40% in <1 year and 26% 1-2 years, 34% of recurrence were target tumor progression, 20% intrahepatic new lesion and 12% both, total deaths were 46% of patients. Conclusions: TACE offers a reasonable palliative therapy for HCC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
